公开(公告)号：US20180346520A1

公开(公告)日：2018-12-06

申请号：US15573701

申请日：2016-05-13

申请人： THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND ,  UNIVERSITY OF WASHINGTON

发明人： Barbara K. Felber ,  George N. Pavlakis ,  James I. Mullins ,  Antonio Valentin ,  Siriphan Manocheewa

IPC分类号： C07K14/005 ,  A61K9/00 ,  A61K39/21 ,  A61K39/39 ,  C07K14/535

CPC分类号： C07K14/161 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/572 ,  C12N2740/16234 ,  C12N2740/16271

摘要： The invention provides methods and compositions for eliciting broad immune responses to HIV envelope proteins. The methods include use of nucleic acids constructs that encode conserved elements of HIV Env to induce immune responses.

公开(公告)号：US09670253B2

公开(公告)日：2017-06-06

申请号：US14632869

申请日：2015-02-26

申请人： Beth Israel Deaconess Medical Center, Inc. ,  Los Alamos National Security, LLC

发明人： Dan H. Barouch ,  Bette T. Korber ,  William M. Fischer

IPC分类号： A61K39/21 ,  A61K39/12 ,  A61K39/00 ,  C07K14/005 ,  A61K39/235 ,  A61K39/275 ,  C12N7/00

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K39/235 ,  A61K39/275 ,  A61K2039/53 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/10043 ,  C12N2710/10343 ,  C12N2710/24043 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2740/16322 ,  C12N2740/16334 ,  Y02A50/467

摘要： The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.

公开(公告)号：US09630996B2

公开(公告)日：2017-04-25

申请号：US14368102

申请日：2012-12-21

申请人： THE UNIVERSITY OF WESTERN ONTARIO

发明人： Chil-Yong Kang ,  Gyoung Nyoun Kim

IPC分类号： A61K39/205 ,  A61K39/00 ,  C07K14/145 ,  C12N7/04 ,  C07K14/005 ,  A61K39/12 ,  C12N7/00

CPC分类号： A61K39/39 ,  A61K39/12 ,  A61K39/205 ,  A61K39/21 ,  A61K39/29 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C12N7/00 ,  C12N7/04 ,  C12N2740/16071 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2740/16334 ,  C12N2760/20221 ,  C12N2760/20222 ,  C12N2760/20234 ,  C12N2760/20243 ,  C12N2760/20262 ,  C12N2760/20271 ,  C12N2770/24234 ,  C12N2770/24271

摘要： The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to a phenylalanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position (22), a leucine changed to a phenylalanine at position (110) and a methionine changed to an arginine at positions (48) and (51). The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher.

公开(公告)号：US20140370043A1

公开(公告)日：2014-12-18

申请号：US14368102

申请日：2012-12-21

申请人： THE UNIVERSITY OF WESTERN ONTARIO

发明人： Chil-Yong Kang ,  Gyoung Nyoun Kim

IPC分类号： C07K14/005 ,  C12N7/00

CPC分类号： A61K39/39 ,  A61K39/12 ,  A61K39/205 ,  A61K39/21 ,  A61K39/29 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55516 ,  A61K2039/57 ,  A61K2039/575 ,  C07K14/005 ,  C12N7/00 ,  C12N7/04 ,  C12N2740/16071 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2740/16334 ,  C12N2760/20221 ,  C12N2760/20222 ,  C12N2760/20234 ,  C12N2760/20243 ,  C12N2760/20262 ,  C12N2760/20271 ,  C12N2770/24234 ,  C12N2770/24271

摘要： The present invention relates to vesicular stomatitis virus (VSV) matrix (M) protein mutants. One mutant M protein includes a glycine changed to a glutamic acid at position (21), a leucine changed to a phenylalanine at position (111) and a methionine changed to an arginine at position (51). Another M protein mutant includes a glycine changed to a glutamic acid at position (22) and a methionine changed to an arginine at positions (48) and (51). Yet another VSV M protein mutant includes a glycine changed to a glutamic acid at position (22), a leucine changed to a phenylalanine at position (110) and a methionine changed to an arginine at positions (48) and (51). The present invention is directed also to recombinant VSVs (rVSV) having these M mutants and to vaccines based on the rVSV having the M mutants of the present invention. These new rVSVs having the mutant M were significantly attenuated and lost virulence, including neurovirulence, and are capable of inducing an immune responses against an antigen of interest. In addition, a rVSV serotype Indiana having the first described M mutant is capable of efficient replication at 31° C., and of poor replication or incapable of replication at about 37° C. or higher.

摘要翻译： 本发明涉及水泡性口炎病毒（VSV）基质（M）蛋白质突变体。 一个突变体M蛋白包括在位置（21）改变为谷氨酸的甘氨酸，在位置（111）将亮氨酸改变为苯丙氨酸，在（51）位置变成精氨酸的甲硫氨酸。 另一个M蛋白突变体包括在位置（22）改变为谷氨酸的甘氨酸和位置（48）和（51）处的甲硫氨酸变为精氨酸。 另一种VSV M蛋白突变体包括在位置（22）改变为谷氨酸的甘氨酸，在位置（110）将亮氨酸变为苯丙氨酸，在位置（48）和（51）将甲硫氨酸变为精氨酸。 本发明还涉及具有这些M突变体的重组VSV（rVSV）和基于具有本发明的M突变体的rVSV的疫苗。 具有突变体M的这些新的rVSV显着减毒并丧失毒力，包括神经毒力，并且能够诱导针对感兴趣的抗原的免疫应答。 此外，具有第一个描述的M突变体的rVSV血清型印第安纳能够在31℃下有效复制，并且在约37℃或更高时能够复制性差或不能复制。

公开(公告)号：US20140093556A1

公开(公告)日：2014-04-03

申请号：US13981671

申请日：2012-01-26

申请人： Francisco Conejero-Lara ,  Irene Luque ,  Pedro Luis Mateo ,  Andreas Wagner ,  Raphaelle Claude ,  Marie-Gaelle Roger ,  Nicolas Mouz ,  Christophe Martin

发明人： Francisco Conejero-Lara ,  Irene Luque ,  Pedro Luis Mateo ,  Andreas Wagner ,  Raphaelle Claude ,  Marie-Gaelle Roger ,  Nicolas Mouz ,  Christophe Martin

IPC分类号： C07K14/005

CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/55555 ,  A61K2039/55572 ,  C07K14/08 ,  C07K14/15 ,  C07K14/155 ,  C07K14/16 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16271

摘要： The disclosure relates to immunological compositions for vaccinating human beings against infection by the Human Immunodeficiency Virus (HIV).

摘要翻译： 本公开涉及针对人类免疫缺陷病毒（HIV）感染人免疫组合物。

公开(公告)号：US20190231866A1

公开(公告)日：2019-08-01

申请号：US16255987

申请日：2019-01-24

申请人： Janssen Vaccines & Prevention B.V.

发明人： Maria Grazia PAU ,  Daniel John STIEH ,  Frank TOMAKA ,  Steven NIJS

IPC分类号： A61K39/21 ,  C12N7/00

CPC分类号： A61K39/21 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55505 ,  A61P31/18 ,  C07K14/161 ,  C07K14/162 ,  C12N7/00 ,  C12N2710/10034 ,  C12N2710/10043 ,  C12N2710/10071 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16234 ,  C12N2740/16271

摘要： Provided are means and methods for generating safe immune responses in humans against multiple clades of human immunodeficiency virus (HIV). The observed immune responses were improved over earlier reported immune responses in clinical trials.

公开(公告)号：US20170360920A1

公开(公告)日：2017-12-21

申请号：US15528230

申请日：2015-11-20

申请人： The Johns Hopkins University

发明人： Robert Siliciano ,  Kai Deng ,  Liang Shan

IPC分类号： A61K39/21 ,  C12N7/00 ,  A61K39/00

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/5158 ,  A61K2039/545 ,  A61K2039/572 ,  C12N7/00 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16234 ,  C12N2740/16271

摘要： Described herein are methods of preventing or treating a HIV infection comprising administering to a mammal in need thereof, a pharmaceutically effective amount of a CD8+ T cell vaccine composition. Such methods comprising using CD8+ T cells which have been pre-stimulated with at least one HIV epitope, to thereby enhance a CD8+ T cell immune response against HIV in said mammal.

公开(公告)号：US20170258890A1

公开(公告)日：2017-09-14

申请号：US15498554

申请日：2017-04-27

申请人： John Coleman ,  Josephine Helena Cox ,  Arban Domi ,  Hiroto Hara ,  Takashi Hironaka ,  Makoto Inoue ,  Dagna Skoog Laufer ,  Angela Grazia Lombardo ,  Christopher L. Parks ,  Eddy Sayeed ,  Maoli Yuan ,  Xinsheng Zhang

发明人： John Coleman ,  Josephine Helena Cox ,  Arban Domi ,  Hiroto Hara ,  Takashi Hironaka ,  Makoto Inoue ,  Dagna Skoog Laufer ,  Angela Grazia Lombardo ,  Christopher L. Parks ,  Eddy Sayeed ,  Maoli Yuan ,  Xinsheng Zhang

IPC分类号： A61K39/21 ,  C07K14/005 ,  C12N15/86 ,  C12N7/00

CPC分类号： A61K39/21 ,  A61K39/12 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/543 ,  A61K2039/545 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/57 ,  A61K2039/575 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N15/86 ,  C12N2740/16034 ,  C12N2740/16134 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2740/16334 ,  C12N2760/18443 ,  C12N2760/18843 ,  C12N2760/18871 ,  C12N2760/20243

摘要： The present invention relates to genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes, methods for making the same and cell substrates qualified for vaccine production which may comprise genetically stable replication competent Sendai virus vector(s) containing optimized HIV genes.

公开(公告)号：US20160237123A1

公开(公告)日：2016-08-18

申请号：US15146511

申请日：2016-05-04

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Loren D. Walensky ,  Gregory H. Bird

IPC分类号： C07K14/005

CPC分类号： C07K14/005 ,  A61K38/162 ,  A61K39/145 ,  A61K39/155 ,  A61K39/21 ,  C07K16/1063 ,  C07K2317/76 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/15071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2760/14022 ,  C12N2760/14034 ,  C12N2760/14071 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2760/18622 ,  C12N2760/18634 ,  C12N2760/18671

摘要： The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized α-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled alpha helical peptides display excellent proteolytic, acid, and thermal stability, restore the native alpha-helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.

公开(公告)号：US20160152667A1

公开(公告)日：2016-06-02

申请号：US15019558

申请日：2016-02-09

申请人： Dana-Farber Cancer Institute, Inc.

发明人： Loren D. Walensky ,  Gregory H. Bird

IPC分类号： C07K14/005 ,  A61K39/145 ,  A61K39/155 ,  A61K39/21 ,  C07K16/10

CPC分类号： C07K14/005 ,  A61K38/162 ,  A61K39/145 ,  A61K39/155 ,  A61K39/21 ,  C07K16/1063 ,  C07K2317/76 ,  C12N2740/15022 ,  C12N2740/15034 ,  C12N2740/15071 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2740/16271 ,  C12N2760/14022 ,  C12N2760/14034 ,  C12N2760/14071 ,  C12N2760/16022 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/18022 ,  C12N2760/18034 ,  C12N2760/18071 ,  C12N2760/18522 ,  C12N2760/18534 ,  C12N2760/18571 ,  C12N2760/18622 ,  C12N2760/18634 ,  C12N2760/18671

摘要： The invention provides compositions, kits and methods utilizing polypeptides having a viral alpha-helix heptad repeat domain in a stabilized α-helical structure (herein also referred to as SAH). The compositions are useful for treating and/or preventing viral infections. The invention is based, at least in part, on the result provided herein demonstrating that viral hydrocarbon stapled alpha helical peptides display excellent proteolytic, acid, and thermal stability, restore the native alpha-helical structure of the peptide, are highly effective in interfering with the viral fusogenic process, and possess superior pharmacokinetic properties compared to the corresponding unmodified peptides.

摘要翻译： 本发明提供了利用在稳定的α-螺旋结构（本文中也称为SAH）中具有病毒α-螺旋七肽重复结构域的多肽的组合物，试剂盒和方法。 该组合物可用于治疗和/或预防病毒感染。 本发明至少部分地基于本文提供的结果，证明病毒性碳氢化合物钉扎的α螺旋肽显示优异的蛋白水解，酸和热稳定性，恢复肽的天然α-螺旋结构，在干扰 病毒融合过程，并且与相应的未修饰的肽相比具有优异的药代动力学性质。